From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage - BiotechTV - News | Lyssna här | Poddtoppen.se
Fler avsnitt av From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage
London based IMU Biosciences announced today that it will use its immune system profiling platform with 80,000 blood samples from UK Biobank to create a large-scale picture of the human immune system
2026-10-19 |
13 min
+
Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1
2026-10-15 |
11 min
+
At Dana-Farber Cancer Institute in Boston, President & CEO Ben Ebert and Professor and Investigator Cigall Kadoch discuss the latest trends in cancer research
2026-10-14 |
19 min
+
Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more
2026-10-07 |
23 min
+
After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress
2026-10-06 |
27 min
+
Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease
2026-10-02 |
20 min
+
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
2026-09-29 |
7 min
+
From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage
2026-09-28 |
9 min
+
From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections
2026-09-28 |
13 min
+
Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study
2026-09-21 |
9 min
+
Podden och tillhörande omslagsbild på den här sidan tillhör
BiotechTV. Innehållet i podden är skapat av BiotechTV och inte av,
eller tillsammans med, Poddtoppen.
En ny version av sidan finns tillgänglig.
Ladda om
Stäng
